Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.

医学 耐受性 无容量 内科学 胃肠病学 队列 不利影响 免疫抑制 进行性疾病 肿瘤科 癌症 外科 疾病 免疫疗法
作者
Adil Daud,Mansoor N. Saleh,James Hu,Jonathan Bleeker,Matthew J. Riese,Roland Meier,Li Zhou,Gulyeter Serbest,Karl D. Lewis
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): 9511-9511 被引量:44
标识
DOI:10.1200/jco.2018.36.15_suppl.9511
摘要

9511 Background: Indoleamine 2,3-dioxygenase 1 (IDO1) enzyme-induced immunosuppression in the tumor microenvironment supports tumor cell evasion of immune surveillance. Epacadostat (E) is a potent and selective oral inhibitor of the IDO1 enzyme. ECHO-204 is an open-label, phase (P) 1/2 study of E plus PD-1 inhibitor nivolumab (N) in patients (pts) with advanced cancer. Updated efficacy and safety/tolerability outcomes for the P2, advanced (unresectable or stage IV) melanoma cohort are reported. Methods: Pts received E (100 or 300 mg PO BID) plus N (240 mg IV Q2W). Response was assessed every 8 weeks (RECIST v1.1). Safety/tolerability was assessed in pts receiving ≥1 study treatment dose. PD-L1 expression was assessed (Dako 28-8 assay; PD-L1 positive: ≥1% tumor cell staining). Results: As of 29 Oct 2017, all of the planned 50 pts were enrolled in the P2 expansion cohort (n = 40 treatment naive for advanced disease). Median (range) duration of follow-up was 417 days (70 to 617 days). Across all pts, overall response rate (ORR) was 62% (31/50; 9 complete response [CR], 22 partial response [PR]) and disease control rate (DCR; CR + PR + stable disease) was 78% (39/50). In treatment-naive pts, ORR was 65% (26/40; 8 CR, 18 PR) and DCR was 80% (32/40); responses were observed in both PD-L1-positive pts (75% ORR [9/12]; 92% DCR [11/12]) and PD-L1-negative pts (56% ORR [9/16]; 69% DCR [11/16]); the majority (88%; 23/26) of responses were ongoing at data cutoff; duration of response ranged 55+ to 565+ days (median not reached); rate of progression-free survival at 6 and 12 months was 77% and 63%, respectively (median not reached); and the rate of overall survival at 12 months was 92% (median not reached). In the overall population (N = 50), the rate of grade ≥3 treatment-related adverse events (TRAEs) was 48% with E 300 mg BID (n = 42; most common grade ≥3 TRAEs: rash [19%], ALT increase [12%]) and 13% with E 100 mg BID (n = 8; pneumonitis [13%] was the only grade ≥3 TRAE). Eight pts discontinued treatment due to TRAEs (all E 300 mg BID). There was no AE-related death. Conclusions: E + N continues to show promising antitumor activity in pts with advanced melanoma and is generally well tolerated. E 100 mg BID is the selected dose for P3 studies of E + N in pts with advanced cancer. Clinical trial information: NCT02327078.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
江南脆饼完成签到,获得积分10
2秒前
2秒前
2秒前
水煮电吹风的应助被Wxiny采纳,获得10
3秒前
冷酷以山发布了新的文献求助30
3秒前
雄关漫道完成签到,获得积分10
4秒前
小杨发布了新的文献求助10
4秒前
香蕉觅云的应助被阿白采纳,获得10
4秒前
莉拉完成签到 ,获得积分10
4秒前
zyl完成签到,获得积分10
4秒前
4秒前
zzww完成签到 ,获得积分10
5秒前
占曼荷完成签到,获得积分20
5秒前
Needle完成签到,获得积分10
5秒前
vickylow发布了新的文献求助10
5秒前
嗝嗝完成签到,获得积分10
6秒前
深情安青的应助被清达采纳,获得10
6秒前
7秒前
南冥发布了新的文献求助10
7秒前
零零柒完成签到,获得积分10
7秒前
风笛发布了新的文献求助10
8秒前
8秒前
工藤新一完成签到,获得积分10
8秒前
elelelelelelel完成签到 ,获得积分10
8秒前
8秒前
yj发布了新的文献求助10
9秒前
Ann发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
11秒前
11秒前
11秒前
Humingyu发布了新的文献求助10
12秒前
mayunrou3759完成签到 ,获得积分10
12秒前
Maestro_S的应助被青争采纳,获得10
12秒前
坦率的萝莉完成签到 ,获得积分10
13秒前
Eliauk完成签到,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519